Prescription of Sacubitril/Valsartan in Patients with Heart Failure and Reduced Ejection Fraction Attending an Outpatient Heart Failure Clinic

Prescription of Sacubitril/Valsartan in Patients with Heart Failure and Reduced Ejection Fraction Attending an Outpatient Heart Failure Clinic

Bibliographic Details
Main Authors:	M Rizzo, I Colomer-Asenjo, M Sutil-Vega, G Cabello-Molina, S Marín-López, F Taibi-Hajjami, C Roca-Guerrero, D García-Vega, M Panelo-Rubio, M Bonastre-Thio, A Martínez-Rubio
Format:	Article
Language:	English
Published:	Radcliffe Medical Media 2020-05-01
Series:	European Cardiology Review
Online Access:	https://www.ecrjournal.com/articleindex/ecr.2020.15.1.PO8

Similar Items

Tolerability Profile and Discontinuation Causes of Sacubitril/Valsartan Treatment in ‘Real-life’ Patients with Heart Failure and Reduced Ejection Fraction
by: M Rizzo, et al.
Published: (2020-05-01)

Sacubitril/Valsartan for heart failure
by: Wenqin Dai, MM, et al.
Published: (2022-06-01)

Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction
by: Muhammad Nauman Khan, et al.
Published: (2023-03-01)

Progress and prospects of Sacubitril/Valsartan: Based on heart failure with preserved ejection fraction
by: Ruoyu Jia, et al.
Published: (2022-11-01)

Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction
by: Zanfina Ademi, et al.
Published: (2017-11-01)

Dapagliflozin versus sacubitril–valsartan for heart failure with mildly reduced or preserved ejection fraction
by: Ronen Arbel, et al.
Published: (2024-03-01)

Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan
by: Jawad H. Butt, et al.
Published: (2024-02-01)

Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry
by: Aldo P. Maggioni, et al.
Published: (2022-12-01)

Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction
by: Mi‐Gil Moon, et al.
Published: (2021-06-01)

Up-Titration of Sacubitril/Valsartan Among Patients With Heart Failure and Preserved Ejection Fraction
by: Koichiro Matsumura MD, et al.
Published: (2023-01-01)

Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction
by: Mauro Gori, et al.
Published: (2021-04-01)

Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction
by: Stephen J. Greene, et al.
Published: (2021-08-01)

Sacubitril/Valsartan Improves Autonomic Function and Cardiopulmonary Parameters in Patients with Heart Failure with Reduced Ejection Fraction
by: Francesco Giallauria, et al.
Published: (2020-06-01)

The emerging role of sacubitril/valsartan in pulmonary hypertension with heart failure
by: Yu Xu, et al.
Published: (2023-05-01)

Effects of Sacubitril/Valsartan on the Right Ventricular Arterial Coupling in Patients with Heart Failure with Reduced Ejection Fraction
by: Daniele Masarone, et al.
Published: (2020-09-01)

Is Sacubitril/Valsartan Able to Change the Timing for Implantation of Cardiac Devices in Heart Failure with Reduced Ejection Fraction?
by: Marta Afonso Nogueira, et al.
Published: (2022-08-01)

Combined treatment with sacubitril/valsartan plus dapagliflozin in patients affected by heart failure with reduced ejection fraction
by: Juan Jiang, et al.
Published: (2023-03-01)

Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in heart failure with reduced ejection fraction in Argentina
by: Mariano A. Giorgi, et al.
Published: (2023-02-01)

Dose titration of sacubitril/valsartan for heart failure with reduced ejection fraction: a real‐world study
by: Chen Wang, et al.
Published: (2023-06-01)

Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial
by: Lars H. Lund, et al.
Published: (2022-02-01)

Duration of Heart Failure With Reduced Ejection Fraction Associated With Electrocardiographic Outcomes Before and After Sacubitril/Valsartan
by: Po-Lin Lin MD, et al.
Published: (2022-06-01)

The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients
by: Ji‐Hye Oh, et al.
Published: (2022-08-01)

Effects of sacubitril/valsartan in patients with cancer therapy-related heart failure
by: Marina V. Vitsenya, et al.
Published: (2023-09-01)

Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: Real-World Experience from Italy (the REAL.IT Study)
by: Andrea Di Lenarda, et al.
Published: (2023-01-01)

The Impact of Sacubitril / Valsartan Versus ACE/ARB Therapy on Functional Capacity in Heart Failure with Reduced Ejection Fraction
by: Mohammad Yassen
Published: (2023-05-01)

The Impact of Sacubitril / Valsartan Versus ACE/ARB Therapy on Functional Capacity in Heart Failure with Preserved Ejection Fraction
by: Mohammad Yassen
Published: (2023-05-01)

Incremental value of mineralocorticoid receptor antagonists in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan
by: Burkert Pieske, et al.
Published: (2022-12-01)

Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?
by: Josep Lupón, et al.
Published: (2021-01-01)

Impact of sacubitril/valsartan on cardiac and systemic hypoxia in chronic heart failure
by: Hélène Nougué, et al.
Published: (2024-01-01)

Impact of Financial Considerations on Willingness to Take Sacubitril/Valsartan for Heart Failure
by: Birju R. Rao, et al.
Published: (2022-06-01)

Impact of Sacubitril/Valsartan on Circulating microRNA in Patients with Heart Failure
by: Maura Brioschi, et al.
Published: (2023-03-01)

Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure
by: Diana-Carina Iovanovici, et al.
Published: (2022-09-01)

Mechanistic Efficacy of Sacubitril/Valsartan in Ischemic Versus Nonischemic Heart Failure
by: Reza Mohebi, et al.
Published: (2023-04-01)

Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials
by: Amr Abdin, et al.
Published: (2022-12-01)

Use and Out‐of‐Pocket Cost of Sacubitril‐Valsartan in Patients With Heart Failure
by: Supriya Shore, et al.
Published: (2022-09-01)

Sacubitril/Valsartan for Heart Failure: Exciting Times but Are Doctors Informed and Ready?
by: Prithwish Banerjee
Published: (2017-01-01)

Sacubitril/Valsartan Improves Left Atrial and Ventricular Strain and Strain Rate in Patients with Heart Failure with Reduced Ejection Fraction
by: Pedro Garcia Brás, et al.
Published: (2023-04-01)

Effects of switching from sacubitril/valsartan to valsartan alone on plasma levels of natriuretic peptides and myocardial remodeling in heart failure with reduced ejection fraction
by: Akihiro Nakamura, et al.
Published: (2023-01-01)

The PARAGON Heart Failure trial – ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction
by: Sverre E. Kjeldsen, et al.
Published: (2019-07-01)

EFFECTS OF SACUBITRIL/VALSARTAN ON THE ARTERIAL STIFFNESS AND LEFT VENTRICULAR-ARTERIAL COUPLING IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
by: Zh. D. Kobalava, et al.
Published: (2018-05-01)